A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?

被引:12
作者
Cross, J. Helen [1 ,2 ,3 ]
Cock, Hannah [4 ,5 ]
机构
[1] UCL NIHR BRC Great Ormond St Inst Child Hlth, Guilford St, London WC1N 1EH, England
[2] Great Ormond St Children NHS Trust, Great Ormond St, London WC1N 3JH, England
[3] Young Epilepsy, Surrey, England
[4] St Georges Univ London, Inst Mol & Clin Sci, London SW17 0RE, England
[5] St Georges Univ Hosp NHS Fdn Trust, Atkinson Morley Reg Epilepsy Network, Blackshaw Rd, London SW17 0QT, England
基金
英国工程与自然科学研究理事会;
关键词
Cannabidiol; Epilepsy; Dravet syndrome; Lennox Gastaut syndrome; Cannabis based medicinal products; TREATMENT-RESISTANT EPILEPSY; ANTIEPILEPTIC DRUGS; CANNABIDIOL; SEIZURES; TRIAL; ACCURACY; EXTRACTS; RECEPTOR; HISTORY;
D O I
10.1016/j.neuropharm.2019.107861
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
With the licensing of cannabidiol for drug resistant seizures in Dravet and Lennox Gastaut syndromes in the United states in 2018, interest in the potential for cannabis-based-medicinal products to meet currently unmet needs for people with epilepsy continues to grow. This review summarizes current knowledge and discusses the implications for future research and practice. Both cannabidiol and tetrahydrocannabinol, the main components, have been extensively studied in animal models, with multimodal mechanisms of action proposed. Only pure cannabidiol formulations have been rigorously evaluated in controlled trials thus far, with modest but significant improvements in motor seizures. Adverse effects include diarrhoea, somnolence and reduced appetite, with mostly acceptable tolerability, but a not insignificant (up to 1 in 23) risk of serious adverse events. Recognized drug interactions include with valproate (increased risk of hepatotoxicity) and clobazam (contributing to somnolence, increased secretions, probably chest infections, and potentially efficacy). Whilst there is public (and producer) interest in products also containing tetrahydrocannabinol, clinicians have justifiable concerns about exposing a group already vulnerable to mental health and neurobehavioural comorbidities to the associated additional risks in these domains. Artisanal preparations, with often inconsistent/unknown constituents are frequently used but not recommended. A gulf exists between the actual evidence, including a lack of comparative studies and public beliefs, fuelled by media and anecdote. Continued education of the public, policymakers, researchers and healthcare providers about what is and isn't yet known, together with on-going good quality research is essential to mitigate against future potential risks, particularly in relation to vulnerable populations. This article is part of the special issue entitled 'New Epilepsy Therapies for the 21st Century - From Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy'.
引用
收藏
页数:7
相关论文
共 60 条
  • [31] Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
    Lattanzi, Simona
    Brigo, Francesco
    Trinka, Eugen
    Zaccara, Gaetano
    Cagnetti, Claudia
    Del Giovane, Cinzia
    Silvestrini, Mauro
    [J]. DRUGS, 2018, 78 (17) : 1791 - 1804
  • [32] The value of the number-needed-to-treat method in antiepileptic drug trials
    Lesaffre, E
    Boon, P
    Pledger, GW
    [J]. EPILEPSIA, 2000, 41 (04) : 440 - 446
  • [33] Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies
    Lorenzetti, Valentina
    Chye, Yann
    Silva, Pedro
    Solowij, Nadia
    Roberts, Carl A.
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2019, 269 (01) : 59 - 71
  • [34] A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome
    McCoy, Blathnaid
    Wang, Laura
    Zak, Maria
    Al-Mehmadi, Sameer
    Kabir, Nadia
    Alhadid, Kenda
    McDonald, Kyla
    Zhang, Grace
    Sharma, Rohit
    Whitney, Robyn
    Sinopoli, Katia
    Snead, O. Carter, III
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2018, 5 (09): : 1077 - 1088
  • [35] Mula M., 2014, European Journal of Neurology, V22, P24
  • [36] Development of a rational scale to assess the harm of drugs of potential misuse
    Nutt, David
    King, Leslie A.
    Saulsbury, William
    Blakemore, Colin
    [J]. LANCET, 2007, 369 (9566) : 1047 - 1053
  • [37] Cannabinoids in treatment-resistant epilepsy: A review
    O'Connell, Brooke K.
    Gloss, David
    Devinsky, Orrin
    [J]. EPILEPSY & BEHAVIOR, 2017, 70 : 341 - 348
  • [38] Obrien T.J., 2019, TRANSDERMAL CANNABID
  • [39] Assessing Conceptual Knowledge in Three Online Engineering Courses: Theory of Computation and Compiler Construction, Operating Systems, and Signal and Systems
    Pamplona, Sonia
    Seoane, Isaac
    Bravo-Agapito, Javier
    [J]. PROCEEDINGS OF THE FIRST INTERNATIONAL CONFERENCE ON DATA SCIENCE, E-LEARNING AND INFORMATION SYSTEMS 2018 (DATA'18), 2018,
  • [40] Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models
    Patra, Pabitra Hriday
    Barker-Haliski, Melissa
    White, H. Steve
    Whalley, Benjamin J.
    Glyn, Sarah
    Sandhu, Haramrit
    Jones, Nicholas
    Bazelot, Michael
    Williams, Claire M.
    McNeish, Alister James
    [J]. EPILEPSIA, 2019, 60 (02) : 303 - 314